President Donald Trump announced nine new agreements with pharmaceutical companies on Monday, August 31, intended to lower the cost of certain medications. These "most-favored-nation" deals aim to encourage companies to launch new medicines in the United States at prices similar to those in other wealthy nations and provide lower prices for existing drugs to state Medicaid programs. The nine participating companies are Alcon, Astellas Pharma, BeOne Medicines, BridgeBio, CSL, Kyowa Kirin, Sun Pharma, Teva Pharmaceuticals, and UCB.
The administration has reached similar agreements with 26 pharmaceutical companies to date. These deals involve commitments from the manufacturers to lower prices and increase domestic manufacturing. In return, many of these companies receive exemptions from potential future tariffs. While the administration has highlighted these deals as an effort toward health care affordability, the specific terms, including which drugs are affected and the exact size of the discounts, have not been publicly disclosed.
Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. stated he is willing to release the details of these agreements, excluding proprietary information and trade secrets, though the agency has not yet done so. Democratic senators, including Elizabeth Warren (D-Mass.) and Ron Wyden (D-Ore.), have criticized the lack of transparency, calling for the disclosure of the promises made by the companies. Additionally, some critics noted that the voluntary nature of the deals could allow companies to withdraw from the agreements in the future.
President Trump has requested that Congress codify these agreements into permanent law to ensure long-term compliance, though he also suggested that his pressure campaign might make legislation unnecessary. The Pharmaceutical Research and Manufacturers of America (PhRMA) stated that these are individual company decisions based on unique circumstances. They argued that private agreements differ from government-mandated price setting, which they claim could affect U.S. competitiveness and fail to address the underlying causes of affordability issues.
Separately, the White House recently released a series of arcade-style games on its website, including one titled "Build the Wall." The game, which tasks players with constructing a border structure to repel a "Zombie Border Siege," drew a warning from the owners of the game Tetris regarding copyright infringement. The Tetris brand stated on Friday, September 4, that it was reviewing the matter for potential copyright infringement and emphasized that it was not involved in the creation of the White House game, which it alleged mimics its mechanics.
For the average consumer, the immediate impact may be felt through the TrumpRx.gov website, which offers coupons and assistance programs for those who are uninsured or paying out-of-pocket for non-covered drugs. However, health policy experts and advocacy groups like Public Citizen note that the actual financial benefit remains difficult to quantify without access to the confidential details of the 26 corporate deals. A person would only notice a change in their bills or at the pharmacy counter if their specific medication is included in the undisclosed list of discounted products.
The primary knock-on effect is the potential shift in how drug prices are set in the U.S., moving toward international reference pricing. While the administration seeks to make these changes permanent through legislation, the voluntary nature of the deals creates uncertainty regarding their longevity. What happens next depends on congressional action; while the president has called for these deals to be codified into law, the proposal faces industry lobbying and opposition from some members of his own party. No specific date for a vote has been reported.